Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Next Previous
X
Search
Trial Profile

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PRECISION
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

    • Most Recent Events

    • 05 Sep 2024 According to an Idorsia Pharmaceuticals Media Release, A biomarker analysis from this PRECISION study will be presented as poster presentation by Martine Clozel, Poster session 2, salon D, on Sep 6 and as oral presentation by Martine Clozel, Session 12 A, Anti-hypertensive drugs, on Sep 6 at at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5-8, 2024.
    • 01 Jul 2024 According to an Idorsia Pharmaceuticals Media Release, European Commission (EC) has approved JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. Company will now work to expand marketing authorization by also applying for JERAYGO approval in the UK, Canada, and Switzerland.
    • 03 Jun 2024 Results assessing the % of subjects with controlled blood pressure according to hypertension guidelines at different timepoints during the study, presented at the 33rd European meeting on hypertension and cardiovascular protection.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top